Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Krzysztof Chylinski

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
RNA Biology|April 9, 2013
The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systemsKrzysztof Chylinski, Anaïs Le Rhun, Emmanuelle Charpentier
Nucleic Acids Research|April 15, 2014
Classification and evolution of type II CRISPR-Cas systemsKrzysztof Chylinski, Kira S Makarova, Emmanuelle Charpentier, et al.
RNA Biology|November 19, 2015
RNA sequencing uncovers antisense RNAs and novel small RNAs in Streptococcus pyogenesAnaïs Le Rhun, Yan Yan Beer, Johan Reimegård, et al.
Science (New York, N.Y.)|June 30, 2012
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunityMartin Jinek, Krzysztof Chylinski, Ines Fonfara, et al.
Nucleic Acids Research|November 26, 2013
Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systemsInes Fonfara, Anaïs Le Rhun, Krzysztof Chylinski, et al.
Nature Chemical Biology|March 4, 2020
Bridge helix arginines play a critical role in Cas9 sensitivity to mismatchesMajda Bratovič, Ines Fonfara, Krzysztof Chylinski, et al.
Nature Communications|December 1, 2019
CRISPR-Switch regulates sgRNA activity by Cre recombination for sequential editing of two lociKrzysztof Chylinski, Maria Hubmann, Ruth E Hanna, et al.
Nature|April 2, 2011
CRISPR RNA maturation by trans-encoded small RNA and host factor RNase IIIElitza Deltcheva, Krzysztof Chylinski, Cynthia M Sharma, et al.
Nature Communications|September 6, 2023
A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivoBurcu Bestas, Sandra Wimberger, Dmitrii Degtev, et al.
Cancer Discovery|September 9, 2024
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven CancersBirgit Wilding, Lydia Woelflingseder, Anke Baum, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
RNA Biology|April 9, 2013
The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systemsKrzysztof Chylinski, Anaïs Le Rhun, Emmanuelle Charpentier
Nucleic Acids Research|April 15, 2014
Classification and evolution of type II CRISPR-Cas systemsKrzysztof Chylinski, Kira S Makarova, Emmanuelle Charpentier, et al.
RNA Biology|November 19, 2015
RNA sequencing uncovers antisense RNAs and novel small RNAs in Streptococcus pyogenesAnaïs Le Rhun, Yan Yan Beer, Johan Reimegård, et al.
Science (New York, N.Y.)|June 30, 2012
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunityMartin Jinek, Krzysztof Chylinski, Ines Fonfara, et al.
Nucleic Acids Research|November 26, 2013
Phylogeny of Cas9 determines functional exchangeability of dual-RNA and Cas9 among orthologous type II CRISPR-Cas systemsInes Fonfara, Anaïs Le Rhun, Krzysztof Chylinski, et al.
Nature Chemical Biology|March 4, 2020
Bridge helix arginines play a critical role in Cas9 sensitivity to mismatchesMajda Bratovič, Ines Fonfara, Krzysztof Chylinski, et al.
Nature Communications|December 1, 2019
CRISPR-Switch regulates sgRNA activity by Cre recombination for sequential editing of two lociKrzysztof Chylinski, Maria Hubmann, Ruth E Hanna, et al.
Nature|April 2, 2011
CRISPR RNA maturation by trans-encoded small RNA and host factor RNase IIIElitza Deltcheva, Krzysztof Chylinski, Cynthia M Sharma, et al.
Nature Communications|September 6, 2023
A Type II-B Cas9 nuclease with minimized off-targets and reduced chromosomal translocations in vivoBurcu Bestas, Sandra Wimberger, Dmitrii Degtev, et al.
Cancer Discovery|September 9, 2024
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven CancersBirgit Wilding, Lydia Woelflingseder, Anke Baum, et al.
Pageof 1